title: Vitamin D deficiency in mycosis fungoides and Sézary syndrome patients is similar to other cancer patients.
abstract: BACKGROUND
  The purpose of this study was to determine the prevalence of vitamin D deficiency in CTCL patients and whether supplementation corrects vitamin D deficiency or treatment outcome.
  
  
  METHODS
  Three hundred eleven CTCL patients including 27/311 (8.7%) with Sézary syndrome (SS), 169 cancer controls, and 69 normal controls from the M.D. Anderson clinics had 25(OH)D3 levels determined and categorized as deficient (< 20 ng/mL),insufficient (20-29 ng/mL), or sufficient (≥ 30 ng/mL). Clinical response was determined according to a change in percent body surface area involvement.
  
  
  RESULTS
  Low 25(OH)D3 (< 30 ng/mL) levels were present in 76.9% of mycosis fungoides/SS patients, 75.2% of cancer controls, and 66.7% of healthy controls (P ¼ .05, .07) and in 30% to 39% of historical normal controls. Correction of deficiency was successful in 35% or 55 of 156 patients who were given dealer's choice of either vitamin D2 at 50,000 IU orally (p.o.) biweekly or D3 1000 IU p.o. daily. Correction of vitamin D levels was noted in 27 of 100 (27%) patients given D3 and 28 of 56 (50%) given D2. Responses to standard CTCL therapy was similar among patients with corrected and persistently low levels (P ¼ .51).
  
  
  CONCLUSIONS
  To our knowledge,this is the first study of vitamin D status in CTCL patients. Vitamin D deficiency was present in CTCL and other cancer patients compared with normal and historical controls. Correction of vitamin D deficiency and type of vitamin D supplementation used did not affect the overall clinical disease response.
authors.forename: Rakhshandra
authors.initials: R
authors.lastname: Talpur
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Cox
authors.forename: Mimi
authors.initials: M
authors.lastname: Hu
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Geddes
authors.forename: Mary K
authors.initials: MK
authors.lastname: Parker
authors.forename: Betty Y
authors.initials: BY
authors.lastname: Yang
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Armstrong
authors.forename: Ping
authors.initials: P
authors.lastname: Liu
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D009367:Neoplasm Staging; D009369:Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D012751:Sezary Syndrome / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D016896:Treatment Outcome; D014807:Vitamin D / Q000008:administration & dosage / Q000097:blood; D014808:Vitamin D Deficiency / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D055815:Young Adult
chemical_list: D014807:Vitamin D